Tag

Eli Lilly

All articles tagged with #eli lilly

health14 days ago•2 min saved

UK approves Lilly’s oral weight‑loss pill as EU decision lags

Britain’s MHRA approved Eli Lilly’s Foundayo (orforglipron) for weight management and type 2 diabetes, marking Lilly’s first European license for the oral GLP-1 drug. The EU decision is not expected until next year. An NHS coverage decision will be made by NICE on November 18, with initial access likely in the private market; Novo Nordisk’s Wegovy pill is expected to reach EU markets soon, increasing competition. The UK remains the only country with a bilateral deal with the US to pay more for medicines.

via politico.eu|

#eli-lilly #foundayo #glp-1

health14 days ago•18 min saved

Florida Alzheimer’s Patient Sees Brain Plaques Clear After 18 Months on Kisunla Therapy

A 79-year-old Pompano Beach man with Alzheimer's completed 18 months of Kisunla infusions to target amyloid plaques, and a final PET scan showed the plaques had cleared. Doctors say the anti-amyloid therapy slows cognitive decline but is not a cure, and Broward Health North's Memory Disorder & Alzheimer's Center is treating more than 60 patients with Kisunla.

via VINnews|

#alzheimers #amyloid-plaques #broward-health-north

business19 days ago•4 min saved

Lilly widens GLP-1 lead as Novo's growth path faces questions

Eli Lilly beat estimates again, lifted full-year guidance, and extended its lead in the GLP-1 obesity/diabetes market with strong demand for Mounjaro and Zepbound, sending the stock higher. Novo Nordisk also beat and raised guidance but faced investor skepticism over its growth trajectory after Wegovy missed expectations, mixed results for its experimental CagriSema, and concerns about pipeline diversification. The market remains bifurcated: Lilly is seen as the momentum winner, while Novo grapples with turning around its growth story despite European expansion and Wegovy's continued rollout, including a September German launch.

via CNBC|

#business #eli-lilly #glp-1

markets20 days ago•151 min saved

Lilly Earnings May Trigger a $65.9B Market Move

Benzinga Pro's earnings watchlist centers on Eli Lilly as the marquee name, with Lilly’s second-quarter print carrying an implied move of about 6.56%—roughly $65.9 billion at stake, the largest dollar swing among the list of big names that includes Disney, Uber, Shopify, AppLovin, Western Digital, and Sandisk; other stocks show implied moves ranging from about 5.5% to 15.5%, reflecting varying levels of volatility expected around earnings.

via Benzinga|

#earnings #eli-lilly #implied-move

healthcare21 days ago•3 min saved

Lilly widens early-access for unapproved obesity drug retatrutide

Eli Lilly says it will allow more patients to apply for pre-approval access to retatrutide, the unapproved obesity drug, after previously granting access to a single 79‑year‑old patient; the company is reviewing requests from doctors in line with FDA guidance.

via STAT|

#eli-lilly #expanded-access #fda-guidance

business1 month ago•3 min saved

Lilly targets 2027 filing for next-gen obesity drug retatrutide after strong Phase 3 results

Eli Lilly said it will file for retatrutide's approval in Q1 2027 after two positive Phase 3 trials showing substantial weight loss and improved glycemic control in adults with obesity and either Type 2 diabetes or cardiovascular disease; the company needs more time to finalize manufacturing data, and retatrutide—a triple-hormone GLP-1/GIP/glucagon drug—could become a key obesity treatment alongside Zepbound and Foundayo.

via CNBC|

#business #eli-lilly #glp-1gipglucagon

health1 month ago•18 min saved

GLP-1 ad war goes to court as Novo Nordisk accuses Lilly of misleading Wegovy–Zepbound ads

Novo Nordisk filed a lawsuit alleging Eli Lilly’s GLP-1 weight‑loss ads mislead viewers by comparing Wegovy to Zepbound using Wegovy’s lower-dose data from outdated studies while ignoring Wegovy’s own high‑dose results; Lilly says the ads disclose that the high‑dose Wegovy data isn’t included and defends the head‑to‑head trial as the gold standard.

via The Washington Post|

#eli-lilly #glp-1 #health

business1 month ago•4 min saved

Novo Nordisk Sues Lilly Over Alleged Misleading GLP-1 Advertising

Novo Nordisk has sued Eli Lilly in New Jersey, alleging Lilly’s GLP-1 ads mislead consumers by citing outdated trials that compare Lilly’s high-dose products to lower-dose Novo drugs and omit newer Wegovy data, including a high-dose Wegovy study showing substantial weight loss. Novo seeks a permanent ban on the ads, corrective advertising, and damages, arguing there are no current head-to-head trials supporting Lilly’s claimed superiority; Lilly has not commented.

via CNBC|

#advertising #business #eli-lilly

business1 month ago•6 min saved

Lilly’s Psychedelics Bet Could Kickstart a Pharma M&A Wave

Eli Lilly’s $2.8 billion acquisition of AtaiBeckley, which includes the fast‑acting 5‑MeO‑DMT program BPL‑003 with phase 2b data for treatment‑resistant depression, underscores growing momentum for psychedelic medicines among Big Pharma and could spur further M&A as investors gain confidence and regulatory signals improve; however, logistical and delivery challenges remain, shaping the type of assets likely to be acquired (favoring programs with solid top‑line data and scalable pathways) and keeping an eye on potential targets like GH Research.

via Fierce Biotech|

#business #depression #eli-lilly

business1 month ago•13 min saved

Lilly backs psychedelic depression therapy with AtaiBeckley takeover

Eli Lilly plans to acquire AtaiBeckley, the clinical-stage psychedelic drug developer, in a deal valued at about $2.8 billion upfront and up to $3.8 billion with milestones. Lilly will pay $6.75 per ATAI share in cash, a roughly 26% premium to the previous close, and could hand over an additional $2.50 per share if future clinical/regulatory milestones are hit. The move gives Lilly access to AtaiBeckley’s pipeline (including BPL-003 and VLS-01) aimed at treating treatment-resistant depression by promoting synaptic connectivity, a mechanism distinct from conventional antidepressants. The agreement signals Lilly’s expanded focus on neuroscience and psychedelic therapies, as AtaiBeckley’s stock surged in pre-market trading on the news. Regulatory approvals and closing conditions will determine final execution.

via Yahoo Finance|

#ataibeckley #business #depression-treatment

health1 month ago•2 min saved

Trump’s GLP-1 price bargain lifts drugmakers’ volume, not patients’ savings

STAT reports that the Trump administration’s GLP-1 price plan—$245 a month for Medicare/Medicaid, tied to insurer coverage for all uses with a $50 copay—did not consistently lower prices and instead boosted sales volume for Eli Lilly and Novo Nordisk in some cases.

via statnews.com|

#eli-lilly #glp-1 #health

business1 month ago•3 min saved

FDA PreCheck pilot aims to speed up U.S. drug manufacturing approvals

The FDA has chosen seven companies, including Eli Lilly and Regeneron, to join a PreCheck pilot that lets regulators begin reviewing new manufacturing facilities while they’re under construction, with the goal of catching issues early and potentially shaving up to 14 months from timelines. The program comprises facility readiness guidance and an expedited application submission/inspection process, and targets drugs produced domestically—especially biologics and gene therapies.

via CNBC|

#business #domestic-manufacturing #eli-lilly

business1 month ago•19 min saved

Healthcare Leaders Rally to Fresh Highs as Lilly, J&J and AbbVie Soar

Healthcare stocks outperformed the broader market as Eli Lilly (LLY), Johnson & Johnson (JNJ) and AbbVie (ABBV) hit fresh 52-week highs (with Merck near highs), while biotech names like Moderna led rallies; the Health Care Select Sector SPDR ETF XLV has climbed about 3% year-to-date, signaling renewed investor interest in defensive healthcare plays amid ongoing M&A activity.

via Yahoo Finance|

#business #eli-lilly #healthcare

business2 months ago•19 min saved

Lilly CEO: GLP-1s May Redefine American Healthcare

Eli Lilly CEO David Ricks says GLP-1 drugs could be more transformative than AI, with strong weight‑loss and health benefits that could curb the roughly $1.4 trillion annual obesity‑related healthcare costs. He notes pricing moves and upcoming Medicare access (around $50 a month starting July) could broaden adoption, while Lilly’s tirzepatide program underscores how GLP‑1 therapies might reshape U.S. healthcare and chronic disease management.

via Yahoo Finance|

#business #eli-lilly #glp-1-therapies

health2 months ago•2 min saved

Lilly’s experimental obesity drug reaches a single patient through compassionate use

STAT reports that Eli Lilly and the FDA approved compassionate-use access for retatrutide, an experimental obesity drug, to a 79-year-old man—a move that drew attention from top health officials and highlighted concerns about access to promising therapies before FDA approval.

via statnews.com|

#compassionate-use #eli-lilly #fda